Literature DB >> 25439566

Inhaled steroids in COPD: when should they be used?

Alvar Agusti1, Leonardo M Fabbri2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25439566     DOI： 10.1016/S2213-2600(14)70227-9

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  8 in total

Review 1.  Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?

Authors:  Andrea P Rossi; Erika Zanardi; Mauro Zamboni; Andrea Rossi
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

Review 2.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

Review 3.  Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.

Authors:  Hernan Iannella; Carlos Luna; Grant Waterer
Journal:  Ther Adv Respir Dis       Date:  2016-02-18       Impact factor: 4.031

4.  Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index.

Authors:  Domenico Maurizio Toraldo; Emanuele Rizzo; Luana Conte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-18       Impact factor: 3.000

5.  Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study.

Authors:  Carlos Cabrera; Ciro Casanova; Yolanda Martín; Virginia Mirabal; María Del Carmen Sánchez; Felisa Álvarez; Gabriel Juliá; Pedro Cabrera-Navarro; Miguel Ángel García-Bello; José María Marín; Juan Pablo de-Torres; Miguel Divo; Bartolomé Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-08

Review 6.  Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.

Authors:  Andrea Rossi; Erika Zanardi; Venerino Poletti; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-23

Review 7.  Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.

Authors:  Alan G Kaplan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-11-20

Review 8.  Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Christer Janson
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 3.005
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.